Barré-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871 (1983).

PubMed  Article  Google Scholar 

Gallo, R. C. et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224, 500–503 (1984).

CAS  PubMed  Article  Google Scholar 

Popovic, M., Sarngadharan, M. G., Read, E. & Gallo, R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497–500 (1984).

CAS  PubMed  Article  Google Scholar 

Sarngadharan, M. G., Popovic, M., Bruch, L., Schüpbach, J. & Gallo, R. C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 224, 506–508 (1984).

CAS  PubMed  Article  Google Scholar 

Saag, M. S. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel. JAMA 324, 1651–1669 (2020).

CAS  PubMed  Article  Google Scholar 

UNAIDS. Fact sheet 2021. UNAIDS https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf (2021).

Kumi Smith, M., Jewell, B. L., Hallett, T. B. & Cohen, M. S. Treatment of HIV for the prevention of transmission in discordant couples and at the population level. Adv. Exp. Med. Biol. 1075, 125–162 (2018).

CAS  PubMed  Article  Google Scholar 

Cohen, M. S., Gamble, T. & McCauley, M. Prevention of HIV transmission and the HPTN 052 study. Annu. Rev. Med. 71, 347–360 (2020).

CAS  PubMed  Article  Google Scholar 

Fischer, W. et al. HIV-1 and SARS-CoV-2: patterns in the evolution of two pandemic pathogens. Cell Host Microbe 29, 1093–1110 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Korber, B., Hraber, P., Wagh, K. & Hahn, B. H. Polyvalent vaccine approaches to combat HIV-1 diversity. Immunol. Rev. 275, 230–244 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Haynes, B. F. & Verkoczy, L. Host controls of HIV neutralizing antibodies. Science 344, 588–589 (2014).

PubMed  PubMed Central  Article  Google Scholar 

Kelsoe, G. & Haynes, B. F. Host controls of HIV broadly neutralizing antibody development. Immunol. Rev. 275, 79–88 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kirchhoff, F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8, 55–67 (2010).

CAS  PubMed  Article  Google Scholar 

Watanabe, Y., Bowden, T. A., Wilson, I. A. & Crispin, M. Exploitation of glycosylation in enveloped virus pathobiology. Biochim. Biophys. Acta Gen. Subj. 1863, 1480–1497 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Whitney, J. B. et al. Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat. Commun. 9, 5429 (2018).

CAS  PubMed  PubMed Central  Article  Google Scholar 

McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10, 11–23 (2010). This work presents a key review on the biology of acute HIV-1 infection.

CAS  PubMed  Article  Google Scholar 

Huang, Y. et al. Effect of rAd5-vector HIV-1 preventive vaccines on HIV-1 acquisition: a participant-level meta-analysis of randomized trials. PLoS ONE 10, e0136626 (2015).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089–1100 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Johnson & Johnson and Global Partners. Johnson & Johnson and Global Partners announce results from phase 2b Imbokodo HIV vaccine clinical trial in young women in sub-Saharan Africa; https://www.jnj.com/johnson-johnson-and-global-partners-announce-results-from-phase-2b-imbokodo-hiv-vaccine-clinical-trial-in-young-women-in-sub-saharan-africa (2021).

Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).

CAS  PubMed  Article  Google Scholar 

Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Plotkin, S. A. Updates on immunologic correlates of vaccine-induced protection. Vaccine 38, 2250–2257 (2020). This paper explains the nature and significance of immune correlates of protection from vaccination.

CAS  PubMed  Article  Google Scholar 

Burton, D. R. Advancing an HIV vaccine; advancing vaccinology. Nat. Rev. Immunol. 19, 77–78 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Burton, D. R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396–407 (2012). This key paper outlines the structure-based and germline-targeting strategies for HIV-1 vaccine design.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Haynes, B. F., Kelsoe, G., Harrison, S. C. & Kepler, T. B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30, 423–433 (2012). This key paper outlines B cell lineage HIV-1 vaccine design and its relationship to germline-targeting strategies.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Haynes, B. F. et al. HIV–host interactions: implications for vaccine design. Cell Host Microbe 19, 292–303 (2016). This paper summarizes HIV–host interactions and their effect on HIV vaccination responses.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gray, E. S. et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828–4840 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163–169 (2014). This key paper that shows that ~50% of individuals infected with HIV-1 make some level of bnAbs, although only about 10-15% can make very high and broad serum bnAb levels.

CAS  PubMed  Article  Google Scholar 

Mikell, I. et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7, e1001251 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Simek, M. D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337–7348 (2009).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tomaras, G. D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502–11519 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gao, F. et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158, 481–491 (2014).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469–476 (2013). This first antibody–virus co-evolution study demonstrates the role of the transmitted/founder virus in initiating bnAb lineages and the role of sequential Envs in bnAb maturation.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Williams, L. D. et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci. Immunol. https://doi.org/10.1126/sciimmunol.aal2200 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Bonsignori, M. et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86, 4688–4692 (2012).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sajadi, M. M. Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses. Cell 173, 1783–1795 (2018).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Nduati, E. W. et al. Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination. Aids 35, 1895–1905 (2021).

CAS  PubMed  Article  Google Scholar 

Simonich, C. A. et al. HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 166, 77–87 (2016).

CAS  PubMed  PubMed Central